Nefopam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Nefopam
Accession Number
DB12293
Type
Small Molecule
Groups
Approved, Investigational
Description

Nefopam is under investigation for the prevention of Cholecystitis and Post Anaesthetic Shivering. Nefopam has been investigated for the prevention of Kidney Transplantation.

Structure
Thumb
Synonyms
  • Nefopam
Product Ingredients
IngredientUNIICASInChI Key
Nefopam Hydrochloride685J48E13W23327-57-3CNNVSINJDJNHQK-UHFFFAOYSA-N
Categories
UNII
4UP8060B7J
CAS number
13669-70-0
Weight
Average: 253.345
Monoisotopic: 253.146664236
Chemical Formula
C17H19NO
InChI Key
RGPDEAGGEXEMMM-UHFFFAOYSA-N
InChI
InChI=1S/C17H19NO/c1-18-11-12-19-17(14-7-3-2-4-8-14)16-10-6-5-9-15(16)13-18/h2-10,17H,11-13H2,1H3
IUPAC Name
5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine
SMILES
CN1CCOC(C2=CC=CC=C2)C2=CC=CC=C2C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AceclofenacAceclofenac may increase the analgesic activities of Nefopam.
AcemetacinAcemetacin may increase the analgesic activities of Nefopam.
AcetaminophenAcetaminophen may increase the analgesic activities of Nefopam.
Acetylsalicylic acidAcetylsalicylic acid may increase the analgesic activities of Nefopam.
AlclofenacAlclofenac may increase the analgesic activities of Nefopam.
AlminoprofenAlminoprofen may increase the analgesic activities of Nefopam.
AminophenazoneAminophenazone may increase the analgesic activities of Nefopam.
AntipyrineAntipyrine may increase the analgesic activities of Nefopam.
AntrafenineAntrafenine may increase the analgesic activities of Nefopam.
AzapropazoneAzapropazone may increase the analgesic activities of Nefopam.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Evidence Level

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
4450
PubChem Substance
347828561
ChemSpider
4295
ChEBI
88318
ChEMBL
CHEMBL465026
Wikipedia
Nefopam
ATC Codes
N02BG06 — Nefopam

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedOtherHealthy Volunteers1
2Not Yet RecruitingPreventionPost Anaesthetic Shivering1
2, 3CompletedTreatmentCesarean Section; Complications, Wound, Infection (Following Delivery) / Postoperative pain / Spinal Anaesthesia During the Puerperium1
2, 3CompletedTreatmentHyperalgesia / Pain, Chronic Disease / Postoperative pain1
2, 3CompletedTreatmentLaparotomy1
3CompletedTreatmentDyspnea / Pain NOS1
4RecruitingPreventionGallbladder Inflammation1
4TerminatedTreatmentAnalgesia, Postoperative1
Not AvailableCompletedPreventionNeoplasms, Breast1
Not AvailableCompletedPreventionStomach Neoplasms1
Not AvailableCompletedPreventionTransplantation, Kidney1
Not AvailableCompletedSupportive CarePatients Undergoing Laparoscopic Gastrectomy1
Not AvailableCompletedTreatmentColonic Neoplasms / Diverticulosis, Colonic1
Not AvailableCompletedTreatmentHypothermia1
Not AvailableCompletedTreatmentPain NOS / Thyroidectomy1
Not AvailableRecruitingSupportive CareBreast Neoplasm Malignant Primary1
Not AvailableUnknown StatusPreventionOrthognathic Surgery / Pain NOS1
Not AvailableUnknown StatusTreatmentLumbar Spinal Stenisis or Lumbar Herniated Intervertebral Disc1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0803 mg/mLALOGPS
logP3.16ALOGPS
logP3.4ChemAxon
logS-3.5ALOGPS
pKa (Strongest Basic)7.72ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity78.48 m3·mol-1ChemAxon
Polarizability29.09 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aralkylamines. These are alkylamines in which the alkyl group is substituted at one carbon atom by an aromatic hydrocarbyl group.
Kingdom
Organic compounds
Super Class
Organic nitrogen compounds
Class
Organonitrogen compounds
Sub Class
Amines
Direct Parent
Aralkylamines
Alternative Parents
Benzene and substituted derivatives / Trialkylamines / Oxacyclic compounds / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Aralkylamine / Benzenoid / Monocyclic benzene moiety / Tertiary aliphatic amine / Tertiary amine / Oxacycle / Azacycle / Organoheterocyclic compound / Ether / Dialkyl ether
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:51 / Updated on December 16, 2018 06:59